Avalo reports Q2 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027

Avalo Therapeutics announced its second quarter 2026 results and business updates on August 6, 2026. The company said it plans to initiate a registrational Phase 3 program evaluating abdakibart in HS in the first half of 2027.¹

Avalo also disclosed progress on a second pipeline candidate. The company announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with potential development in HS as well as other inflammatory disorders.¹ Avalo said it expects to submit an Investigational New Drug application for AVTX-010 in the first half of 2027.¹ According to the company, AVTX-010 is engineered on the Fc region to last longer in the body while keeping the same drug activity and target specificity as abdakibart.¹

In corporate news, Avalo said it appointed Ron Philip to its Board of Directors, citing his strategic and commercial experience in bringing new therapies to market.¹ The company was also added to the Russell 2000 and Russell 3000 Indexes as part of the FTSE Russell annual reconstitution.¹

On finances, Avalo reported cash, cash equivalents and investments of $472.2 million as of June 30, 2026.¹ Net cash used in operating activities totaled $37.7 million for the six months ended June 30, 2026.¹ The company said this cash position is expected to fund operations into 2029.¹

Research and development spending rose to $23.4 million for the second quarter of 2026, an increase of $9.3 million from the second quarter of 2025, which the company attributed to a $10.0 million abdakibart development milestone and related HS program costs.¹ Net loss for the quarter was $36.4 million, an increase of $15.6 million from the second quarter of 2025.¹